New clinical evidence of the advantages of lithotripsy treatment of benign prostatic hyperplasia (BPH) using MOSES™ Technology is being presented at the American Urological Association's (AUA) annual meeting, taking place in Chicago, May 3-6, 2019.
Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, announced that it will again be supporting the International Scar Treatment Conference in Israel, which will be held for the second time in Tel Aviv, on March 21st-22nd, 2018.
Last year, at the very first Scar Treatment Conference, the international event allowed key opinion leaders from the USA, Europe and Israel to gather and share important new studies and patient care protocols. Among them were Dr. Jill Waibel, Dr. Peter Shumaker, Dr. Mateo Tretti Clementoni and other leading experts, who spoke about the unique Lumenis UltraPulse® SCAARFX™ solution for severe scar treatment.
“Treatment of scars is my passion and last year’s 2017 International Scars Conference was one of the most informative meetings regarding this topic,” said Dr. Matteo Tretti Clementoni. “Lumenis produces a variety of devices including the UltraPluse CO2, the ResurFX™ (1565 nm non-ablative fractional), and the IPL with OPT™, that allow me to treat most of the scars I see during my everyday activity. Using their devices along or in combination we are not only able to change the features of a scar but also to really improve the quality of life of the patients.”
Under the direction of The Tel Aviv Medical Center, Ichilov, with the Israel Society of Dermatology and Venereology, the Israeli Society for Dermatologic Surgery and the Israeli Society of Plastic and Aesthetic Surgery, the conference will bring together experts from the plastic surgery, aesthetic, and dermatology community worldwide to explore the newest, cutting-edge practices in scar treatment and aesthetics.
“Lumenis is proud to support the second International Scar Treatment Conference in Israel,” said Tzipi Ozer-Armon, CEO of Lumenis. “We take great pride in our meaningful solutions for scar treatments, which not only impact the visibility of scars, but the quality of life of patients who suffer from them.”
Lectures will be held on a diverse range of topics, including scar mitigation and healing, surgery and trauma, therapies for medical management, laser and light therapy, and acne scarring and striae to name just a few. In addition to the presentations, and a live scar treatment workshop, an extensive, professional exhibition will be held to showcase the latest breakthrough innovations in medical equipment and the pharmaceutical industry worldwide, including a section featuring Lumenis breakthroughs, such as the UltraPulse® SCAARFX™, M22™ - multi application platform, and AcuPulse™.
On Wednesday, March 21st and Thursday, March 22nd the Lumenis UltraPulse® SCAARFX™, M22™ - multi application platform, and AcuPulse™ complete aesthetic workstation will be the focus of over 20 lectures at the Scars II Conference. Highlights include, live scar treatments workshop by world renowned experts, “Ameliorating pain and itch”, by Dr. William Norbury, “Algorithm for laser scar treatment”, by Dr. Matteo Tretti Clementoni, and more. Please visit lumenis.com for a detailed agenda.
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are forward-looking statements. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties these forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether a result of new information, future events or otherwise.
For further information, contact 5W Public Relations at Lumenis@5wpr.com.
Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, today announced the launch of its new Moses™ Holmium technology during the 112th American Urological Association (AUA) annual meeting in Boston. The AUA launch of Moses follows a successful introduction of the technology during the last European Association of Urologists (EAU) annual congress in London, where hundreds of physicians had a firsthand experience of the Moses technology – stressing its truly innovative nature and potential to revolutionize the world of holmium laser lithotripsy.
Moses is a breakthrough patent pending technology that redefines holmium laser lithotripsy as it exists today. Through a proprietary combination of holmium laser systems and fibers, Moses optimizes laser energy transmission to increase stone ablation volume while reducing dependency on the working distance between the fiber and stone. Further, the unique Moses pulse modulation reduces stone retropulsion and, in-turn, stone migration, leading to a more efficient treatment and greater physician control over the procedure. The Moses tailored premium fiber range of 200, 365, and 550 D/F/L is designed for optimal energy transmission and durability. Additionally, the Moses 200 D/F/L fiber allows surgeons to treat stones in difficult to reach locations, and enables smooth initial fiber insertion through a deflected scope.
The innovative Moses Holmium technology was acknowledged by the AUA’s scientific committee as it was chosen to be presented during the AUA Stone Disease Surgical Therapy podium session. This session will include the pre-clinical study done by Prof. Mostafa Elhilali of McGill University Health Center Department of Urology in Montreal, Canada, who passed away two weeks ago. Prof. Elhilali, who led the pre-clinical and clinical evaluation of the Moses Technology, was a world-renowned urologist, and a longtime partner and friend of Lumenis. His findings will be presented by his research partner, Dr. Sero Andonian of McGill University, who noted: “Prof. Elhilali has made legendary contributions to clinical education, and innovations in surgery and urology at large. I am honored to present our jointly pioneered studies on the Moses technology. Our initial findings showed that Moses is a true breakthrough in holmium laser lithotripsy, providing enhanced physician control and procedural efficiency. I look forward to continuing the research started by Prof. Elhilali, and further understanding the benefits of the Moses Technology”.
Moses is currently being evaluated further by additional leading global experts. Dr. Khurshid Ghani, Assistant Professor of Urology at the University of Michigan, said: “I am very excited to be one of the first physicians worldwide to evaluate the new Moses Technology. In the first few cases I performed I noticed better control of the stone and less dependency on the distance of the fiber from the stone.” Dr. Andrew Symes, Consultant Urological Surgeon, Brighton & Sussex University Hospital NHS Trust, UK, who will present his findings during the AUA annual meeting, said: “The Moses technology provides a greater sense of control due to minimized retropulsion. This is particularly valuable when dusting large stones in the kidney, but also when dealing with upper ureteric stones”.
To celebrate the launch of the breakthrough Moses Holmium Technology, Lumenis has invited six-time NBA Most Valuable Player and six-time NBA champion, Kareem Abdul-Jabbar to join the Lumenis booth for the triumphant product release. The NBA’s all-time leading scorer will participate in the ribbon cutting ceremony for the Moses Holmium together with Lumenis CEO, Tzipi Ozer-Armon, who said:
“It is a great privilege to introduce this ground-breaking innovation, the result of decades of Holmium experience and generations of commitment to better technology for better patient care. We are honored to be accompanied by Mr. Abdul-Jabbar, a symbol of longevity and excellence in the game of basketball, and a true example of achievement of the highest level.”
The Company’s Comprehensive Set of Activities at the ELS Congress Strengthens Collaboration with the ENT Surgical Community
Lumenis UltraPulse laser is being used to treat Phan Thị Kim Phúc's remnant scars from the 1972 errant napalm bombing of her village. In Nick Ut's Pulitzer Prize winning "Napalm Girl" photo of Phan Thị Kim Phúcand other children fleeing from a Napalm bombing during the Vietnam War has long been a symbol of the horrors of that war.
John Cramer of DC Progressive reports that trading volume on Lumenis stock was unusually heavy this Wednesday (Oct. 7), with an increase of 65% over the previous session.
CNN Money reported that Lumenis Ltd. and XIO Group jointly announced today that the merger transaction under which XIO Group will acquire Lumenis for $14.00 per share in cash, is expected to close by October 18, 2015.
Stock Transcript listed Lumenis as one of the "Hot Stocks" as a result of its shareholders approving the proposed merger with XIO.